M ost cases of tuberculosis (TB) in the United States occur among non-US born residents. 1 Previous studies suggest that testing and treatment with isoniazid for latent TB infection (LTBI) among non-US born persons is cost-effective. 2 Common comorbidities among non-US born persons, such as diabetes, end-stage renal disease (ESRD), and HIV infection, increase the risk of TB reactivation while carrying competing risks of death that may limit the health benefits of testing and treatment. 3 Since the publication of previous cost-effectiveness analyses, the treatment regimen of rifapentine and isoniazid administered weekly for 3 months by directly observed therapy and self-administration was found to be safe, effective, and cost-effective among LTBI patients in the United States. [4] [5] [6] [7] The economic value of LTBI testing and 3 months of treatment with self-administered rifapentine and isoniazid in non-US born patients with medical comorbidities is not clear. 3, 8 There are multiple LTBI testing strategies, including tuberculin skin tests (TSTs), interferon gamma release assays (IGRAs), and combinations of the 2 measures. Centers for Disease Control and Prevention guidance for testing and treatment of LTBI suggests that, in some patients, using 2 tests together to maximize the sensitivity of the LTBI testing algorithm is appropriate, but the long-term benefits and value of such combined testing approaches are not certain. [9] [10] [11] [12] [13] We used a decision-analytic Markov model to estimate clinical outcomes, costs, and cost-effectiveness of testing for and treatment of LTBI among non-US born persons in the United States. We considered testing with TST, IGRA, or in combination, and included 3 months of LTBI treatment with selfadministered rifapentine and isoniazid. The results are intended to inform health care professionals seeking guidance on LTBI testing and policymakers seeking to recommend costeffective interventions.
Methods

Overview
We developed a simulation model to investigate LTBI testing and treatment in 4 non-US born populations: with no comorbidities, with diabetes, with HIV, and with ESRD. Outcomes from the model include the number needed to test and treat (NNT) to prevent 1 case of reactivation TB, life expectancy, discounted qualityadjusted life expectancy, discounted lifetime medical costs, and incremental cost-effectiveness ratios (ICERs). All cost outcomes are reported in 2015 US dollars. The study was approved by Harvard University Institutional Review Board.
Model Structure
The model includes 2 components: a decision tree capturing outcomes relating to testing and a Markov model simulating the lifetime progression of a cohort of people. We developed the model using TreeAge software, version 2015 (TreeAge Corp).
Decision Tree
We modeled 5 testing strategies: no testing, TST, IGRA, confirm positive (patients with a positive TST given IGRA, with both positive resulting in LTBI diagnosis), and confirm negative (patients with a negative IGRA given TST, with either positive resulting in LTBI diagnosis). The branches of the decision tree capture the prevalence of LTBI, the probability of testing positive, and the probability of initiating treatment. Patients may be lost to followup before TST reading. At the ends of each branch in the decision tree, patients are separated into 4 groups to be "handed off" to the Markov model: LTBI with treatment, LTBI without treatment, no LTBI with treatment, and no LTBI without treatment.
Markov Model
The Markov model simulates long-term outcomes related to the natural history of LTBI, including progression to active TB (reactivation) and mortality from TB or other causes. The rate of TB reactivation decreases as the cohort ages. Across risk groups, a proportion with active TB develops severe TB disease, characterized by higher medical costs, hospitalization, and increased risk of death. Outpatient treatment of TB is associated with 6 months of increased mortality, decreased quality of life, and additional costs associated with treatment, while severe TB lasts for 9 months. Patients who survive TB are cured with no further risk of TB reactivation.
We modeled LTBI therapy as 3 months of self-administered rifapentine and isoniazid 4, [14] [15] [16] and assumed that LTBI treatment without toxic effects causes no change in quality of life. Completed LTBI therapy reduces the monthly probability of TB reactivation. Patients can withdraw from therapy due to toxic effects (adding 1 month of additional cost and qualityof-life decrement and possibility of death) or nonadherence. We assumed no partial protection for those who withdraw. For each case of reactivation TB, we modeled additional TB cases due to transmission. Each secondary case results in additional cost and decreased life expectancy, estimated as the difference in outcomes between a healthy 35-year-old and a 35-year-old individual with active TB. We did not consider transmission beyond the first generation.
We modeled age-and sex-specific mortality from causes other than TB; non-US born patients with no comorbidities have the same competing risks of death as the US general population. We modeled elevated mortality and increased medical costs among the non-US born patients with diabetes, with HIV, and with ESRD cohorts. [17] [18] [19] Despite a high prevalence of diabetes in the ESRD population, our model does not distinguish between those cohorts. The additional cost and risk of death from ESRD is greater than any other differences between these subpopulations.
Model Data
We conducted a meta-analysis to estimate the diagnostic performance of TST and IGRA (eAppendix in the Supplement). 20 Using a Bayesian latent class model, we predicted test characteristics for each risk group, which are reported in Table 1 .
We selected model parameters from medical literature (Table 1) . Miramontes et al 40 reported LTBI prevalence in non-US born individuals of 15.9% using National Health and Nutrition Examination Survey data. We used an 18% failure of non-US born persons to return for TST reading reported by Desale et al. 25 We applied a rate of TB reactivation without LTBI treatment in the general non-US born population of 104 cases per 100 000 person-years at risk. 22, 41 For each decade after simulation start, we assumed a 10% reduction in the base reactivation rate due to self-cure. 42 Monthly risk of reactivation was higher in populations with comorbidities. The non-US born patients with diabetes and non-US born patients with ESRD had 1.8 times the monthly rate of reactivation of non-US born patients with no comorbidities, 29 while the baseline reactivation rate for non-US born patients with HIV was 3.5 times higher. 28 Completed LTBI treatment confers a 90% reduction in the modeled rate of reactivation. 4 Medicare-allowable fees were applied as cost estimates for IGRA and TST ($84.35 vs $7.87). 32 Therapy costs accrued monthly; patients who failed to complete the course did not incur the full cost of treatment ($582). 32, 34, 43 Treatment-related toxic effects resulted in an additional $323 in medical costs, and the rare event of toxicity-induced death added $13 782. 32, 33, 44 The cost of severe TB requiring hospitalization was roughly 10 times that of outpatient TB treatment ($28 692 vs $2900). 32, 33, 44 Quality of life with LTBI and during LTBI therapy was 1.0. Quality of life with treatment-related toxic effects was 0.75 during the month with toxic effects and 0.83 with active tuberculosis.
38,39
Statistical Analysis
The analysis assumed a health care sector perspective and lifetime horizon with a 3% annual discount to costs and benefits. 45 We assumed a commonly cited willingness-to-pay threshold of $100 000 per quality-adjusted life-year (QALY) gained. 46 We conducted deterministic sensitivity analyses, systematically altering model parameters to observe their effect on conclusions. Parameters of interest included test characteristics, LTBI prevalence, age of cohort (which relates to remaining life expectancy and cumulative TB risk), and quality-oflife estimates. Second-order Monte Carlo simulation was used to conduct 10 000 probabilistic sensitivity analyses, and LTBI prevalence, test characteristics, and the rate of reactivation TB were incorporated. We sampled TST and IGRA test characteristics from joint distributions; both prevalence of LTBI and baseline rate of reactivation were sampled from uniform random distributions.
Results
Across all non-US born risk populations studied, testing and treatment for LTBI prevented TB cases, contributed to gains in QALYs, and increased cost ( Table 2) . No testing resulted in the worst health outcomes at the least cost. The confirm positive strategy provided greater health outcomes than no testing and was the next strategy to be least costly. Although TST provided better health outcomes than confirm positive, it did so at a greater cost per QALY than IGRA; therefore, TST was excluded from ICER calculations through the principle of ex- tended dominance. IGRA provided greater health outcomes than the confirm positive strategy. The confirm negative strategy delivered the best health outcomes. Since the choice of strategy depends on payer willingness to pay by population, we present results for each risk population below ( Figure 1 ).
Non-US Born Patients With No Comorbidities Cohort
Among non-US born patients with no comorbidities, IGRA prevented 50% of lifetime TB reactivation compared with no testing (0.30% vs 0.60% in the total cohort), had an NNT of 332, and was associated with an ICER of $83 000/QALY. Confirm negative prevented 13% more TB reactivation cases than IGRA, had an NNT of 294, and was associated with an ICER of $147 000/QALY.
Non-US Born Patients With Diabetes Cohort
Among non-US born patients with diabetes, confirm positive prevented 28% of lifetime TB reactivation compared with no testing (0.36% vs 0.50% in the total cohort), had an NNT of 749, and was associated with an ICER of $53 000/QALY. IGRA prevented 50% of lifetime TB reactivation cases, had an NNT of 409, and was associated with an ICER of $120 000/QALY. Confirm negative prevented 56% of lifetime TB reactivation cases, was associated with the lowest NNT of 362, and had an ICER of $230 000/QALY.
Non-US Born Patients With HIV Cohort
Among non-US born patients with HIV, confirm negative prevented 55% of lifetime TB reactivation (0.72% vs 1.59%), had a relatively low NNT of 114, and was associated with an ICER of $63 000/QALY.
Non-US Born Patients With ESRD Cohort
For the non-US born patients with ESRD population, competing risks of death greatly limited remaining life expectancy and therefore also reduced the lifetime risk of TB reactivation. Testing for LTBI improved QALYs, but ICERs for all strategies were over $2 million/QALY gained.
Sensitivity Analysis
We varied the inputs to the model to test whether our conclusions were robust under different circumstances and whether any general patterns could be discerned to help inform the choice of testing strategy. In general, the base case conclusions were robust to changes in core model parameters.
LTBI Prevalence
In populations with high LTBI prevalence, the confirm negative approach is most cost-effective ( Figure 2 ). For example, confirm negative was the preferred strategy for non-US born patients with no comorbidities when prevalence was greater than 23% (base case, 15.9%) and it was preferred for non-US born patients with diabetes when the prevalence of LTBI was greater than 34%. Among the non-US born patients with ESRD population, no feasible LTBI prevalence resulted in testing being costeffective. At no plausible LTBI prevalence among non-US born persons was the no testing strategy preferred for risk populations other than ESRD. Among the non-US born patients with no comorbidities cohort, when prevalence is between 2.5% and 12.5%, confirm positive is the preferred option (ICER, $38 000/ QALY); if the prevalence is below 2.5%, then no testing is preferred. Similarly, among the non-US born patients with diabetes cohort, confirm positive had an ICER of less than $100 000/QALY unless prevalence is less than 4.5%, at which point no testing is preferred. Among the non-US born patients with HIV cohort, IGRA remained cost-effective even at a prevalence of less than 1%.
TST Specificity
With modest improvement in specificity, TST became a costeffective strategy. For example, when TST specificity among the non-US born patients with no comorbidities cohort was greater than 92.5% (base case, 88.6%), TST became the preferred strategy, and the ICER for IGRA compared with TST was just over the willingness-to-pay threshold ($103 000/ QALY). However, decreases in TST specificity resulted in IGRA becoming the preferred choice. For example, in the non-US born patients with diabetes cohort with TST specificity less than 64%, IGRA became the preferred strategy, with an ICER compared with confirm positive of $100 000/ QALY. 
TST Return Rate
Only substantial improvements in rates of follow-up made TST cost-effective ( Figure 2 ). For example, among the non-US born patients with no comorbidities cohort when more than 91.5% of individuals returned (base case, 82%), TST became the preferred strategy (ICER compared with confirm positive, $86 000/ QALY). When return for TST in the non-US born patients with diabetes cohort was less than 58%, IGRA was the costeffective strategy.
Age
Some form of testing and treatment was cost-effective regardless of age. In younger persons, the cumulative lifetime risk of reactivation is higher than in older persons; therefore, more sensitive testing algorithms became economically attractive. For example, when we assumed the non-US born patients with diabetes population was younger (35 years), IGRA became the preferred strategy (ICER, $59 000/QALY compared with confirm positive). Likewise, a further reduction in age among non-US born patients with diabetes to 30 years resulted in confirm negative being the preferred strategy (ICER, $100 000/QALY).
Quality of Life With LTBI and Post-TB
If living with LTBI carried any associated disutility (0.99), then confirm negative became clearly preferred for all groups other than non-US born patients with ESRD. If recovering from TB conveyed permanent pulmonary sequelae associated with modest disutility, 47 strategies using IGRA were preferred for all groups other than non-US born patients with ESRD. Confirm negative was preferred when the health state utility of cured TB was less than 0.97 among non-US born patients with no comorbidities and when it was less than 0.87 for the non-US born patients with diabetes cohort.
Probabilistic Sensitivity Analysis
Among the non-US born patients with no comorbidities cohort, some form of LTBI testing was cost-effective in more than 90% of simulations ( Figure 3) . IGRA was the preferred strat- A, A 1-way sensitivity analysis demonstrating the effect of TST return on the cost-effectiveness conclusions for interferon gamma release assay (IGRA) testing and IGRA plus TST for sensitivity testing. B, An illustration of the effect of LTBI prevalence on cost-effectiveness conclusions for IGRA testing and confirm negative testing. In the confirm negative strategy, patients first underwent IGRA. If that test was positive, LTBI was diagnosed. If that test was negative, then the patient underwent TST. LTBI was ruled out only if both tests were negative. For each risk population, there is a unique LTBI prevalence above which IGRA requires more investment to gain the same amount of quality-adjusted life-years (QALYs) than confirm negative. Above this point, IGRA is excluded from consideration as a viable strategy and thus is not represented in the figure. The apparent discontinuity at high prevalence (>90% non-US born patients with diabetes, >80% non-US born individuals with no comorbidities) emerges when confirm negative is not only a cost-effective strategy but becomes more favorable than other, less costly strategies. Incremental cost-effectiveness ratios (ICERs) are calculated against the next-best alternative strategy and are shown in 2015 US dollars per QALY gained. End-stage renal disease was excluded from this figure because it is cost-ineffective.
egy in 29% of simulations, confirm negative was preferred for 20%, confirm positive was preferred in 17% of simulations, and TST was the preferred strategy in 25% of simulations. For the non-US born patients with diabetes cohort, some form of testing was cost-effective in all simulations. Confirm positive was the preferred strategy in 39.5% of the simulations, and IGRA was preferred in 21.8%; TST was the preferred strategy in 38.7% of the simulations.
For the non-US born patients with HIV cohort, confirm negative was the preferred strategy in 63% of simulations, IGRA was preferred 31% of the time, and TST was preferred in 6% of the cases. Confirm positive was preferred in fewer than 1% of the simulations. Finally, for the non-US born patients with ESRD cohort, no testing was the preferred strategy in 100% of the simulations.
Discussion
We used simulation modeling to project the long-term outcomes and cost-effectiveness of strategies for testing and treating LTBI among non-US born individuals with and without common comorbidities. First, we found that testing for LTBI in non-US born individuals followed by 3 months of self-administered rifapentine and isoniazid therapy prevents reactivation TB, improves health outcomes, and is cost-effective compared with no LTBI testing or treatment. The exception is for non-US born patients with ESRD, where competing risks of death substantially reduce the benefits of treatment such that no testing is costeffective.
Second, we demonstrated that TST alone-one common approach to testing-is likely not the best use of limited TB control resources among non-US born persons. In over 60% of the simulations for the non-US born patients with no comorbidities and non-US born patients with diabetes and in 94% of simulations for the non-US born patients with HIV cohort, some sequence of testing with IGRA was preferred. Both lower specificity and loss to follow-up associated with TST reduce its cost-effectiveness. If only testing cost is considered in the design of TB control strategies, TST might be selected despite the fact that IGRA provides better outcomes per dollar spent. Tuberculosis control programs can use these results to identify effective candidate strategies. Third, we found that, among non-US born patients with HIV in whom both the prevalence of LTBI and the risk of reactivation are high, testing algorithms should maximize test sensitivity to approach treatment for all cases of LTBI. Among non-US born patients with HIV, the confirm negative algorithm suggested in current Centers for Disease Control and Prevention guidance is economically attractive, assuming a $100 000 willingness-to-pay threshold. 13 Among the non-US born patients with no comorbidities and non-US born patients with diabetes, the choice of how to use IGRA-either alone or in combination with TST to maximize either specificity or sensitivity-is more complex. Our probabilistic sensitivity analyses results highlight the level of uncertainty in this decision. Some sequence of IGRA testing was preferred in the majority of simulations, but each algorithm that used IGRA had a similar probability of being preferred at a willingness-to-pay threshold of less than $100 000/QALY. The single-variable sensitivity analyses, however, shed some light on the dynamics behind this uncertainty and should help decision makers to navigate this obstacle. The cost-effectiveness of TST is highly dependent on its specificity and return rate. For non-US born patients with no comorbidities, IGRA provides a 1-step testing algorithm that has good health outcomes and whose ICER is below a $100 000 willingness-topay threshold; for non-US born patients with diabetes, the ICER for IGRA was $120 000/QALY, just over a $100 000 willingnessto-pay threshold. Although a strict interpretation recommends confirm positive as the preferred strategy for the non-US born patients with diabetes population, the sensitivity of this conclusion to key parameters, such as LTBI prevalence and TST return, suggests that it is not definite. When policymakers consider additional factors that were not explicitly modeled, such as patient convenience and the desire to publish simple, effective guidance applicable to all non-US born individuals, evidence mounts to recommend 1-step IGRA testing for both the non-US born patients with no comorbidities and non-US born patients with diabetes groups. With additional available resources or a prevalence of LTBI approaching the high end of estimates, it is likely reasonable to follow-up a negative IGRA with a TST for added sensitivity.
Limitations
It is notable that LTBI testing and treatment among non-US born patients with ESRD was not cost-effective. Among patients undergoing dialysis, competing risks of death limit life expectancy, which reduces the remaining years at risk for developing TB and limits the benefit of preventing TB. One limitation of our study is that the model only considered 1 generation of TB transmission. While we did not find that LTBI treatment was likely to be cost-effective among non-US born patients with ESRD, another rationale for TB testing in dialysis centers might be to prevent TB outbreaks in hospitals and ensure infection control.
There are additional limitations to this study. The prevalence of LTBI and the test characteristics of TST and IGRA are impossible to directly observe and difficult to estimate without a reference standard for LTBI diagnosis. One strength of our analysis is the synthesis of multiple data sources to inform TST and IGRA sensitivity and specificity. We used second-order Monte Carlo simulation to test the robustness of base-case conclusions and transparently demonstrate the quantitative effect of such uncertainty on our conclusions. Similarly, the rate of TB reactivation over decades of remaining life is uncertain. We modeled decreasing reactivation over time, consistent with observational data, and also explored the impact of reactivation rates in probabilistic sensitivity analyses. In addition, if we were to implement a societal framework through which to consider costs and benefits, the additional costs to patients due to the need to return for a TST reading may further reduce the appeal of strategies using TST.
Conclusions
This study highlights the need for observational research about the relative performance of tests for LTBI as well as the necessity of less costly, better-performing tests. A single test with improved characteristics and a lower cost than that of IGRA could reduce investment needed in terms of patient and provider time and cost and make universal testing for non-US born patients even more attractive.
Targeted testing and treatment for LTBI remains a cornerstone of the US TB elimination plan. We found that LTBI testing and treatment among non-US born persons with comorbidities, including diabetes and HIV, prevents cases of TB, improves quality-adjusted life expectancy, and is costeffective. Targeted testing and treatment for LTBI among non-US born people with and without common comorbidities, using IGRAs and 3 months of self-administered rifapentine and isoniazid, are effective and provide good value for the resources invested. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 1 and it is these personsoften unaware of their infection and untreated-who represent the majority of our TB cases today and in the future. The good news is that TB disease can be prevented through testing and treatment of LTBI. To make TB prevention even simpler, we now have a safer, shorter, effective treatment regimen. 2 Why then have clinicians across the United States been slow to identify, test, and treat those at risk? A major hurdle has been a lack of clarity on whom and how to test and treat. In 2016, the US Preventive Services Task Force recommended focusing testing and treatment of LTBI on 2 main groups: non-US born residents and residents of congregate settings.
3 National guidelines followed in 2017 recommending interferon gamma release assays (IGRAs) as the preferred test in most patients. 4 In this issue of JAMA Internal Medicine, Tasillo et al 5 investigate LTBI testing and treatment in non-US born residents of the United States with and without comorbidities. The authors modeled testing approaches for non-US born patients with HIV, end-stage renal disease (ESRD), and diabetes, as well as non-US born patients without a coexisting condition. They investigated the cost-effectiveness of using a single test (either IGRA or tuberculin skin test [TST]) or dual testing strategies. The analysis showed that, compared with no testing, it is cost-effective to test and treat non-US born US residents for LTBI. The analysis also showed that costeffectiveness of testing and treatment compared with no testing was not dependent on age. The TST alone was not an optimal testing strategy in any group because of lower specificity and poor return rates, despite its lower cost. Thus, the modeling results underscore recent guidance that IGRA is the preferred test for most patients. 4 The exception to cost-effectiveness was for those with ESRD whose short-term survival reduces the TB prevention benefit. Because patients with ESRD typically spend many hours in a congregate health care setting, screening and treating non-US born patients with ESRD may be warranted to protect others despite a lack of cost-effectiveness in this analysis.
We believe that the results of the study support implementation of a simple testing strategy of IGRA alone for most non-US born residents of the United States. Although the testing strategies that were most cost-effective differed somewhat, by population, testing with IGRA alone was favored for the non-US born individuals without a comorbidity and also was favorable in those who had diabetes, a condition that confers a moderate risk of progression. For HIV-infected non-US born patients, sequential testing using IGRA and TST (confirmed negative) proved to be the optimal approach because maximum sensitivity is desired. Testing this group would start with an IGRA and, only if the results were negative, a TST would be performed. Although the authors focus on HIV as a condition that greatly increases TB progression risk, it makes sense for clinicians to extend the findings to immunosuppression resulting from anti-tumor necrosis factor agents, prolonged use of high-dose corticosteroids, and organ transplantation, all of which are growing in frequency. The strategy of enhanced testing with IGRA followed by TST if IGRA testing is negative deserves consideration in non-US born patients with immunosuppressed states caused by these medications.
The authors model used the shortest effective treatment: the 12-dose regimen of rifapentine and isoniazid (once per week) that has significantly better treatment completion rates and lower hepatotoxicity than isoniazid alone. 2 Although the initial trial evaluated rifapentine and isoniazid for 12 weeks under directly observed therapy, self-administration of these drugs was found to be noninferior to directly observed administration in US patients. 6 By modeling self-administered treatment, the authors provide additional support for this more practical and less costly approach. We anticipate that this approach will become routine practice and national guidance will follow shortly. Clinicians are faced with daily decisions about whether to provide tests or treatment that will offer a benefit and to avoid 
eAppendix. Meta-analysis
Introduction
The goal of this analysis is to investigate the relative costs and health benefits associated with testing and treatment for latent tuberculosis infection (LTBI) in foreign-born U.S.
residents. We sought to determine which strategy or strategies are cost-effective in the U.S. healthcare system.
Our analysis is conducted through a computer model that we designed to simulate the lifetime progression of a cohort of people with and without latent tuberculosis infection (LTBI). The model is constructed using TreeAge software version 2016 (TreeAge Corporation, Williamstown, MA). Through this model we simulate both the cascade of testing, diagnosis and treatment for LTBI and the remaining lifetime health outcomes of TB morbidity, mortality, and quality adjusted life years gained (QALYs). We use population-level averages of costs and health outcomes to calculate incremental costeffectiveness measures and draw conclusions about which strategies being studied are most cost effective for clinical practice.
Research Question
For each population studied we developed a model with similar structure but different input values to identify which, if any, of the selected testing strategies would be most cost effective to achieve the greatest QALYs at a commonly used willingness to pay (WTP) cost threshold of $100,000 per QALY gained.
Populations of Interest
We defined four populations of interest: foreign-born with no comorbidities (FB-NC), foreign-born with diabetes mellitus (FB-D), foreign-born with HIV (FB-HIV), and foreign-born with end v-stage renal disease (FB-ESRD). These populations have different life expectancies, associated healthcare costs and rates of TB reactivation.
Costs
We applied economic costs from the healthcare sector perspective. All costs in our analysis are reported in 2015 dollars; any costs from literature reported in other years were adjusted using an online calculator reflecting the Consumer Price Index (CPI) found at www.usinflationcalculator.com. We assumed that average costs from various data sources for the U.S. population overall would be equivalent to those specifically for FB populations. We used U.S. age-and sex-specific averages of background healthcare costs for the FB-NC population; we estimated costs using payments for care as reported by the sources overestimate to some extent actual economic costs, they are the best estimates of costs that we were able to obtain.
Life Expectancy
The FB-NC population has a life expectancy without LTBI of 80 years, consistent with that of the general U.S. population. 5 The FB-HIV population has a life expectancy without LTBI of 69 years. 4, 6 The FB-D population has a life expectancy without LTBI of 75 years. 7 The FB-ESRD population has a life expectancy without LTBI of 69 years. 8 On general, life expectancy is decreased in those with LTBI due to the risk of TB reactivation and subsequent possibility of death.
Testing Strategies
No testing In this strategy, no testing is performed. Thus, no TB cases are prevented, no individuals initiate LTBI treatment and the risk of TB reactivation throughout the lifetime is unmitigated.
TST In this strategy, a tuberculin skin test (TST) is placed and patients are required to return within 48 to 72 hours to have the results read. In the base case, 82% of patients returned to have their TST read, while the remainder are lost to follow up. 9 The results of this single test are considered to be final-those with a positive result are diagnosed with LTBI while those with a negative result receive no further clinical intervention. 
IGRA
Test Characteristics
There is no gold standard against which to quantify the performance of commercially-available tests for LTBI. Estimates from the literature are varied and depend heavily on population of interest, especially by age, health status and country of origin. We conducted a thorough review of available literature followed by a comprehensive meta-analysis to estimate the performance of both TST and IGRA.
Our literature search identified 41 studies reporting the cross-classification of results of TST and IGRA for LTBI in various populations. From these, we extracted cross-classification of results of TST and IGRA by age and by whether subjects: were immigrants; originated from countries with an annual TB case rate greater than 50 per 100,000 population; had history of BCG vaccination; had recent contact with active TB cases; or had a comorbidity of interest, and on the. We developed a Bayesian hierarchical random effects model that treated the unobserved disease status as a latent variable. For each of three comorbid categories (no comorbidities, HIV, diabetes mellitus/ESRD) the model generated probability distributions of the sensitivity and specificity for TST and IGRA. In our primary analysis, we used average test performance from these distributions and assumed test independence (Table S1 ). 
Treatment
We estimate that 90% of individuals diagnosed with LTBI will initiate treatment. 51 We model a regimen of twelve weeks of self-administered high dose isoniazid and rifapentine (3HP). 52 We estimated the cost of this regimen to include the cost of the medicines as well as a monthly physician visit. Of those who initiate treatment, 78.3% are estimated to complete the three-month course.
probability of dropping out of treatment each month, and thus partial cost is accrued for those who do not finish the regimen. Of those who do drop out, a small proportion (<2%) do so due to hepatotoxicity. 52, 53 Of those who develop hepatotoxicity, 0.1% die. 54 Both non-fatal and fatal drug-induced hepatotoxicity are associated with additional cost; for non-fatal cases this includes the cost of two specialty physician visits as well as two liver panels (a total of $323), estimated using Medicare allowable physician fees for a one new and one established physician visit (CPT codes 99203 and 99204) and Medicare allowable lab fees for a liver panel (CPT code 80076). For fatal cases, we estimated the cost of hospitalization with other liver disease at $13,780, obtained from the AHRQ National Inpatient Sample. 55 After the completion of treatment, patients experience a 90% reduction in the monthly risk of tuberculosis. Patients who initiate, but fail to complete, treatment are assumed not to receive any partial benefit.
Reactivation of LTBI
Persons with latent tuberculosis infection are exposed to a probability of TB reactivation every month throughout the simulation. The reactivation rate for foreign-born U.S.
residents based on TST results was adjusted using the Rogan-Gladen calculation to account for the possibility that false-positive and false-negative results might have distorted the true reactivation rate. 56 The rate of reactivation in foreign-born persons reported by Shea, et. al was 98 cases per 100,000 person-years at risk; after correction, the rate used in the model was 104 cases per 100,000 person-years at risk. This probability of reactivation was increased by a factor of 1.8 in persons with either diabetes mellitus or end-stage renal disease. 57 For individuals with HIV, the probability of TB reactivation was adjusted to hit a lifetime target of reactivation for infected and untreated individuals of 10%. 58 This baseline probability of reactivation is decreased by 10% each decade; this reduction in probability accounts for the potential for self-cure of LTBI over time as demonstrated by reductions in TST positivity when individuals are re-tested after ten years. 59 Although epidemiological data may demonstrate increased reactivation in older persons, this is confounded with higher prevalence of disease in earlier birth cohorts. 60 Of those who progress to reactivation TB, 50.3% develop a case severe enough to warrant hospitalization and increased medical attention; we model this through the proportion of individuals developing cavitary tuberculosis. 61 This estimate aligns with the 49% of patients found by Taylor et al to require hospitalization during the course of their TB illness. 62 Non-severe tuberculosis results in excess mortality and cost and decreased quality of life for six months; severe tuberculosis extends for a total of nine months.
Costs associated with tuberculosis include the multi-drug pharmaceutical regimen, clinical visits, chest x-rays, contact tracing and bacterial cultures and total $2,900 in TB treated in an outpatient setting. We assumed that severe disease includes the cost of a hospitalization episode with tuberculosis, obtained from the AHRQ National Inpatient Sample ($25,200). 55 Of those who develop reactivation TB, 5% die, with the majority of deaths concentrated in severe cases. 63 Once a person has survived active TB, they are no longer exposed to the risk of reactivation. For every active case of tuberculosis, we model 0.25 additional cases. 64 The effect of additional cases is the difference in both qualityadjusted life expectancy and lifetime healthcare costs between an otherwise healthy 35 year old and one with tuberculosis.
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Sensitivity Analyses
The results of key sensitivity analyses referenced in manuscript text are presented below. 
FB-NC
